This morning, I received an email from Mark containing a rather nice article from Patently-O. The article, which was an excerpt from an upcoming book, Rethinking Patent Law by Robin Feldman.
I suppose what really pulled me in (and Mark knew it would, I imagine), was
the discussion on the patentability of medical and diagnostic procedures in personalized medicine. If you’re familiar with the Pharmaceutically Speaking series, you already know my general feeling on some of the patents I’ve heard about recently. For the unfamiliar, my usual reaction generally involves something akin to the emotional stages of recovery. First, a double take, a verbal expression of disbelief, pounding my head on the desk in hopes that I can no longer comprehend what I have just read, telling the computer I’ll actually install all the updates if it makes the bad thing go away, and, finally, writing a Tactical IP article about it.
Of course, that isn’t to say that all medical/pharmaceutical patents are wrong. For instance, as much as we dislike having to pay lots of money for new drugs, that’s what funds the research to find newer and better drugs. When you start trying to patent all the immunization schedules ever and a really obvious medical test that involves little more than thought, I may not have very nice things to say to you.
Feldman points this out in the article, thankfully. I don’t feel so alone in my frustration anymore. But the point that both Feldman and I have been making is that mere thought is NOT patentable. Testing apparatus may certainly be patented, and some specific testing methods may be patented, but, even though machine or transformation is not the only test, it’s a pretty good indicator for what should and shouldn’t be considered patentable in the field of medicine.
I titled this article Invention vs Observation, because that is one of the points Feldman makes: invention is patentable, observation is not. That is, the apparatus and the test may be patentable, because you may be creating something there. The observation of the test results, however (which is what the two patents I mentioned effectively attempt to monopolize), has NO inventive concept whatsoever. Feldman also talks about software vs math, and how the line is even fuzzier there. Right now, though, we all know you’re here for your dose of pharma.
In short, I may buy that book, and I hope the Supreme Court does the right thing.









